Explore › Intervention › High-intensity bridging chemotherapy
Intervention

High-intensity bridging chemotherapy

Also known as: High-intensity bridging chemotherapy (myelosuppression >7 days) prior to CAR T cell infusion
3 findings 1 paper 3 related entities View in graph →

Related entities

conditions
Precursor B-cell acute lymphoblastic leukemia in remission1
outcomes
Clinical Outcomes in Routine Evaluation Learning Disabilities1
studys
PMC93613931

Findings (27)

None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →
None
null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

PMC9361393
Finding details → · Paper → · Graph →

Papers (1)